期刊文献+

抗CCP抗体的历史背景及在类风湿性关节炎的应用

下载PDF
导出
摘要 类风湿关节炎(Rheumatoid a rthritis,RA)因其早期症状复杂多样且不典型,常常给临床诊断带来困难,进而延误治疗导致病情进展。故早期诊断是影响RA预后的决定因素。抗环瓜氨酸肽抗体(抗CCP抗体)是类风湿性关节炎(RA)早期诊断的一种较灵敏的标记物。本文就抗CCP抗体的历史背景以及其在类风湿性关节炎中的应用作一综述。
作者 铁宁 李鸿斌
出处 《内蒙古医学杂志》 2010年第S6期31-34,共4页 Inner Mongolia Medical Journal
  • 相关文献

参考文献15

  • 1吴庆军,曾小峰,唐福林,张奉春,董怡,赵岩,田新平,史艳萍,张乃峥.类风湿关节炎早期诊断的血清学研究和临床应用[J].医学研究杂志,2006,35(5):43-44. 被引量:27
  • 2李鸿斌,张奉春.B淋巴细胞克隆清除治疗类风湿关节炎的研究进展[J].中华医学杂志,2005,85(42):3021-3024. 被引量:4
  • 3Thomas D?rner,Karl Egerer,Eugen Feist,Gerd R Burmester.Rheumatoid factor revisited[J].Current Opinion in Rheumatology.2004(3)
  • 4F. A.van Gaalen,S. P.Linn‐Rasker,W. J.van Venrooij,B. A.de Jong,F. C.Breedveld,C. L.Verweij,R. E. M.Toes,T. W. J.Huizinga.Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: A prospective cohort study[J].Arthritis & Rheumatism.2004(3)
  • 5Erik R.Vossenaar,Albert J.W.Zendman,Walther J.van Venrooij,Ger J.M.Pruijn.PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease[J].Bioessays.2003(11)
  • 6Braun-Moscovici Y,Markovits D,Zinder O,et al.Anti-cyclic citrullinated protein antibodies as a predictor of re-sponse to anti-tumor necrosis factor-alpha therapy in pa-tients with rheumatoid arthritis[].The Journal of Rheuma-tology.2006
  • 7Arnett FC,Edworthy SM,Bloch DA,et al.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis[].Arthritis and Rheumatism.1988
  • 8Nienhuis R L F,Mandema E.A new serum factor in patients with rheumatoid arthritis: the antiperinuclear factor[].Annals of the Rheumatic Diseases.1964
  • 9Simon M,Girbal E,Sebbag M,et al.The cytokeratin filament-aggregating protein, filaggrin is the target of the so-called "antikeratin autoantibodies:, autiantibodies specific for rheumatoid arthritis[].Journal of Clinical Investigation The.1993
  • 10Schellekens GA,de Jong BA,van den Hoogen FHJ,et al.Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies[].The Journal of Clinical Investigation.1998

二级参考文献29

  • 1Edwards JC, Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford), 2001,40:205-211.
  • 2De Vita S, Zaja F,Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Arthritis Rheum,2002, 46:2029-2033.
  • 3Leandro MJ, Edwards JCW, Cambridge G.Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis,2002,61:883-888.
  • 4Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med,2004,17,350:2572-2581.
  • 5Hainsworth JD. Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritis.Arthritis Res Ther, 2003,5:S12-16.
  • 6Cambridge G, Leandro MJ, Edwards JC,et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum, 2003,48:2146-2154.
  • 7Szczepan′ ski L, Szechin′ ski J, Filipowicz-Sosnowska A,et al.Infusions of rituximab in patients with rheumatoid arthritis are well tolerated. Ann Rheum Dis, 2003, (Suppl 1):171.
  • 8Moore J, Ma D, Will R,et al. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. Bone Marrow Transplant,2004,34:241-247.
  • 9Bridges SL. Update on autoantibodies in rheumatoid arthritis.Curr Rheumatol Rep,2004,6:343-350.
  • 10Ng YC, Peters DK, Walport MJ. Monoclonal rheumatoid factor-IgG immune complexes. Poor fixation of opsonic C4 and C3 despite efficient complement activation. Arthritis Rheum,1988,31:99-107.

共引文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部